Business Context and Reporting Period
Company: Biofrontera Inc. (BFRI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Biofrontera is a U.S.-based biopharmaceutical company focused on photodynamic therapy (PDT) for dermatological conditions, primarily treating actinic keratosis (AK) with its product Ameluz and RhodoLED Lamps. The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Net Revenues | $41,705 | $37,321 |
| Net Loss | $(10,536) | $(17,759) |
| Loss from Operations | $(11,348) | $(17,210) |
| Adjusted EBITDA | $(10,571) | $(15,258) |
| Cash and Cash Equivalents (Year End) | $6,392 | $5,905 |
| Accumulated Deficit | $(127,945) | $(117,409) |
| Convertible Notes Payable | $4,589 | $4,098 |
Note: The filing text does not provide a specific gross margin percentage, but Cost of Revenues decreased significantly in 2025 due to a strategic transaction.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $4.4 million (11.8%) to $41.7 million, driven by organic growth in Ameluz sales volume and a price increase, partially offset by a decline in RhodoLED Lamp sales.
- Cost Structure Transformation: Cost of revenues, related party, decreased by $7.7 million (43.4%). This was primarily due to the "Strategic Transaction" with the Biofrontera Group, which replaced a transfer pricing model (25% of revenue) with a lower earnout structure (approx. 5% of revenue for sales after July 2025).
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by $4.0 million, largely due to higher legal costs related to patent claims. Research and Development (R&D) expenses increased by $1.6 million as the company assumed full control of U.S. clinical trials.
- Asset Divestiture: The company sold the intangible asset related to its Xepi product line in November 2025 for $3.0 million, recognizing a gain of $0.7 million.
Guidance, Outlook, Risks, and Unusual Items
Strategic Transaction and Outlook
On October 20, 2025, the company finalized an asset acquisition of all U.S. rights to Ameluz and RhodoLED from the Biofrontera Group. This transaction includes a monthly earnout of 12% of U.S. revenues (15% if revenues exceed $65 million annually). Management expects this structure to accelerate the path to break-even. The company plans to expand commercialization of Ameluz and pursue label expansions for superficial basal cell carcinoma (sBCC) and trunk/extremities AK.
Going Concern Warning
Substantial Doubt: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for at least twelve months from the filing date. As of December 31, 2025, cash was $6.4 million, and the company incurred a net cash outflow from operations of $13.4 million. The company plans to address this through revenue growth, milestone payments from the Xepi sale, and potential additional equity or debt financing.
Key Risks and Contingencies
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a closing bid price below $1.00 for 34 consecutive days. It has 180 days (until June 30, 2026) to regain compliance.
- Legal Proceedings: The company is involved in patent infringement litigation with DUSA Pharmaceuticals/Sun Pharmaceutical Industries regarding the RhodoLED XL lamp. An Administrative Law Judge issued an Initial Determination finding the Sun Patents valid and the importation of RhodoLED XL in violation of Section 337 of the Tariff Act. The company is appealing this and challenging the patent validity at the PTAB.
- Supply Chain: The company relies on contract manufacturers in Switzerland and Germany. Geopolitical instability and tariffs on imports from Europe pose a risk to costs and supply continuity.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $6.4 million cash balance against the $13.4 million annual operating cash burn and the timeline for securing additional financing.
- Nasdaq Delisting Risk: Monitor the stock price to ensure it meets the $1.00 threshold for 10 consecutive days before the June 30, 2026 deadline.
- Legal Outcome: Track the status of the International Trade Commission (ITC) review of the RhodoLED XL patent infringement ruling, as an exclusion order could halt U.S. sales.
- Earnout Obligations: Review future cash flow projections against the new 12-15% revenue earnout payable to the Biofrontera Group.
- Regulatory Milestones: Confirm the timeline for the FDA Prescription Drug User Fee Act (PDUFA) decision on the sBCC indication (expected September 28, 2026).